There is no FDA-approved GLP-1 for dogs, and no canine GLP-1 clinical trial has been announced. Akston has disclosed two preclinical dog candidates, AKS-724d and AKS-725d, in its 2026 SEC filing. Both are being tested in mice; the company says promising candidates may advance to laboratory-dog safety and pharmacokinetic work. That is a programme, not a dog trial, and it does not support a 2027 availability claim.
The GLP-1 candidates appear first. LOY-002 and Slentrol remain below them as regulatory and historical context because neither is a GLP-1.
Lab tests, not yet tried in pets
Akston's 2026 SEC S-1/A names both canine candidates and says they are being tested in mice. Candidates with promising results may advance to pharmacokinetic and safety testing in laboratory dogs. Akston also states that it has not engaged regulators about these programmes. No canine clinical trial or commercial timeline has been announced.
Tracked as regulatory and historical context
Two of three FDA technical sections accepted: reasonable expectation of effectiveness in February 2025 and target animal safety in January 2026. The manufacturing section remains outstanding.
The first and so far only FDA-approved canine weight-loss drug. Approved 2007, voluntarily discontinued in 2013.
| Drug | Species | Result expected | Status | Detail |
|---|---|---|---|---|
| PreclinicalLab tests, not yet tried in pets | ||||
| AKS-724d / AKS-725dAkston Biosciences | Dogs | Not applicable | Akston's 2026 SEC S-1/A names both canine candidates and says they are being tested in mice. Candidates with promising results may advance to pharmacokinetic and safety testing in laboratory dogs. Akston also states that it has not engaged regulators about these programmes. No canine clinical trial or commercial timeline has been announced. | Full statusFull status for AKS-724d / AKS-725d |
| Not GLP-1sTracked as regulatory and historical context | ||||
| LOY-002LoyalNot a GLP-1 | Dogs | Company-projected launch before end of 2026Estimate, not confirmed by the company | Two of three FDA technical sections accepted: reasonable expectation of effectiveness in February 2025 and target animal safety in January 2026. The manufacturing section remains outstanding. | Full statusFull status for LOY-002 |
| Slentrol (dirlotapide)Pfizer Animal HealthNot a GLP-1 | Dogs | Not applicable | The first and so far only FDA-approved canine weight-loss drug. Approved 2007, voluntarily discontinued in 2013. | Full statusFull status for Slentrol (dirlotapide) |
Nothing in this table is FDA-approved for weight loss in cats or dogs. A drug being in a pivotal study is not an approval, and an expected date is not a result. Dates marked “estimated” come from news reports or our own analysis, not from the company.
One email when there's real news: Okava MEOW-1 results, FDA filings, the first cat & dog GLP-1 launches. Nothing else.
We never share your email. Unsubscribe in one click. Powered by Resend.
Nothing here is veterinary advice. Human GLP-1 medications are not approved for pet weight loss, and their presence on a human label does not establish a safe canine dose. Do not give your dog your medication; talk to your veterinarian.